{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:26:52Z","timestamp":1792272412554,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.critrevonc.2024.104499","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:49:54Z","timestamp":1725637794000},"page":"104499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma"],"prefix":"10.1016","volume":"204","author":[{"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stuver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104499_bib1","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104499_bib2","unstructured":"ADCETRIS [prescribing information]. Bothell, WA: Seagen Inc, 2023."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104499_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104499_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharm."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2024.104499_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2022-165917","article-title":"Treatment related morbidity in patients with classical Hodgkin lymphoma: Results of the ongoing, randomized phase III HD21 trial by the German Hodgkin Study Group","volume":"140","author":"Borchmann","year":"2022","journal-title":"Blood."},{"issue":"suppl 2","key":"10.1016\/j.critrevonc.2024.104499_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hon.3196_LBA5","article-title":"BrECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin Lymphoma: efficacy results of the GHSG phase III HD21 trial","volume":"41","author":"Borchmann","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104499_bib7","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1182\/bloodadvances.2023010622","article-title":"Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort","volume":"7","author":"Bowers","year":"2023","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104499_bib8","first-page":"732","article-title":"Peripheral Neuropathy: Evaluation and Differential Diagnosis","volume":"102","author":"Castelli","year":"2020","journal-title":"Am. Fam. Physician."},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104499_bib9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104499_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104499_bib11","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/geront\/gnz147","article-title":"A comprehensive overview of activities of daily living in existing frailty instruments: A systematic literature search","volume":"61","author":"Costenoble","year":"2021","journal-title":"Gerontologist."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104499_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11916-022-01061-7","article-title":"Evidence-based treatment of painful diabetic neuropathy: a systematic review","volume":"26","author":"D'Souza","year":"2022","journal-title":"Curr. Pain. Headache Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104499_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104499_bib14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00280-018-3664-y","article-title":"Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy","volume":"82","author":"Farshchian","year":"2018","journal-title":"Cancer Chemother. Pharm."},{"issue":"S2","key":"10.1016\/j.critrevonc.2024.104499_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hon.3164_261","article-title":"Toxicities at one year follow-up in patients with advanced stage classical Hodgkin lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group","volume":"41","author":"Ferdinandus","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2024.104499_bib16","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104499_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","volume":"26","author":"Fu","year":"2023","journal-title":"iScience."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104499_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10654-015-0094-6","article-title":"The epidemiology and risk factors of chronic polyneuropathy","volume":"31","author":"Hanewinckel","year":"2016","journal-title":"Eur. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104499_bib19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial","volume":"20","author":"Hirayama","year":"2015","journal-title":"Int J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104499_bib20","unstructured":"International Council for Harmonisation (2015). MedDRA. Introductory guide for standardised MedDRA queries (SMQs) Version 17.1. Retrieved December 22 from \u3008https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_17_1_english.pdf\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104499_bib21","first-page":"38","article-title":"Drug-induced peripheral neuropathy: a narrative review","volume":"15","author":"Jones","year":"2020","journal-title":"Curr. Clin. Pharm."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104499_bib22","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.critrevonc.2024.104499_bib23","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1200\/JCO.2024.42.16_suppl.12046","article-title":"Impact of chemotherapy-induced peripheral neuropathy permanence on patients' preference to discontinue chemotherapy","volume":"42","author":"Jun","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104499_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104499_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1055\/s-0039-1691749","article-title":"Laboratory evaluation of peripheral neuropathy","volume":"39","author":"Lau","year":"2019","journal-title":"Semin. Neurol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104499_bib26","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1097\/NCC.0b013e318299ad23","article-title":"Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"36","author":"Lavoie Smith","year":"2013","journal-title":"Cancer Nurs."},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104499_bib27","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104499_bib28","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1007\/s00520-021-06042-x","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Maih\u00f6fner","year":"2021","journal-title":"Support. Care Cancer."},{"issue":"34","key":"10.1016\/j.critrevonc.2024.104499_bib29","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01357","article-title":"Integrative medicine for pain management in oncology: Society for Integrative Oncology--ASCO guideline","volume":"40","author":"Mao","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104499_bib30","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9980","key":"10.1016\/j.critrevonc.2024.104499_bib31","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet."},{"issue":"5_suppl","key":"10.1016\/j.critrevonc.2024.104499_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2017.35.5_suppl.120","article-title":"Brentuximab-induced peripheral neuropathy: Risk factors and patient experiences","volume":"35","author":"Nagle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104499_bib33","unstructured":"National Institutes of Health. National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. Retrieved September 9 from https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104499_bib34","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104499_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17474086.2022.2080050","article-title":"A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed\/refractory classical Hodgkin lymphoma","volume":"15","author":"Raut","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104499_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1134436","article-title":"Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years","volume":"14","author":"Ruggiero","year":"2023","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104499_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40261-019-00882-6","article-title":"Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial","volume":"40","author":"Salehifar","year":"2020","journal-title":"Clin. Drug Invest."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104499_bib38","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized Clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.critrevonc.2024.104499_bib39","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1182\/bloodadvances.2023010700","article-title":"Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced stage Hodgkin lymphoma","volume":"24","author":"Steiner","year":"2023","journal-title":"Blood Adv. 7"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104499_bib40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104499_bib41","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104499_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.critrevonc.2024.104499_bib43","unstructured":"VINBLASTIN [Prescribing information]. Lake Zurich, IL: Fresenius Kabi; 2016."},{"key":"10.1016\/j.critrevonc.2024.104499_bib44","doi-asserted-by":"crossref","unstructured":"Yasenchak, C.A., Flinn, I.W., Melear, J., Ramchandren, R., Friedman, J., Burke, J.M., Linhares, Y., Gonzales, P., Raval, M., Chintapatla, R., Feldman, T.A., Yimer, H., Islas-Ohlmayerl, M., Dean, A., Rana, V., Gandhi, M.D., Renshaw, J., Ho, L., Fanale, M.A., Guo, W., Lee, H.J. (2023). Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced-stage classical Hodgkin lymphoma: updated efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part B). Abstract P1064 presented at the European Hematology Association, Frankfurt, Germany June 5-18, 2023.","DOI":"10.1097\/01.HS9.0000971152.58813.12"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104499_bib45","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104499_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104499_bib47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2021004970","article-title":"Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma","volume":"6","author":"Zinzani","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104499_fur1","unstructured":"National Cancer Institute. (2023). Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Hodgkin lymphoma. Retrieved August 11 from \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html\u3009."},{"key":"10.1016\/j.critrevonc.2024.104499_fur2","unstructured":"National Cancer Institute. (17 February 2023). PRO-CTAE. Retrieved August 10 from \u3008https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/instrument.html\u3009."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T04:03:02Z","timestamp":1732939382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"alternative-id":["S1040842824002427"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104499","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104499"}}